Kodiak Sciences Announces First Time Presentation of Primary Endpoint Data From Tarcocimab Tedromer Phase 3 GLOW Study in Patients With Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

By / 02/11/2023

Kodiak Sciences Inc announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology to be held November 3-6 in San Francisco.